WO1994027628A1 - Enteral nutritional product - Google Patents

Enteral nutritional product Download PDF

Info

Publication number
WO1994027628A1
WO1994027628A1 PCT/US1994/005415 US9405415W WO9427628A1 WO 1994027628 A1 WO1994027628 A1 WO 1994027628A1 US 9405415 W US9405415 W US 9405415W WO 9427628 A1 WO9427628 A1 WO 9427628A1
Authority
WO
WIPO (PCT)
Prior art keywords
nutritional product
product
blend
range
fatty acids
Prior art date
Application number
PCT/US1994/005415
Other languages
French (fr)
Inventor
Frederick Oliver Cope
Linda Sue Rausch
Ernest William Richards
Michelle Marie Smith
Bonnie Chandler Abbruzzese
Joan Marie Pero
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to EP94917991A priority Critical patent/EP0700303A4/en
Publication of WO1994027628A1 publication Critical patent/WO1994027628A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/01Hydrolysed proteins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/175Amino acids
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present invention relates to an enteral nutritional supplement, for example for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy.
  • Cancer patients typically undergo intermittent periods of chemotherapy and/or radiation therapy during which their nutritional needs are different from the periods between therapy treatments. It is preferred that when the patient is not receiving intensive therapy a well balanced enteral diet be consumed. However, decreased appetite and changes in taste perceptions due to therapies may result in inadequate nutritional intake. Therefore, the consumption of an enteral nutritional supplement may be required.
  • the nutritional product of the present invention is formulated to provide enteral nutritional supplementation, for example for a person afflicted with cancer, during a period of time when the person is not undergoing intensive chemotherapy and/or radiation therapy. That is to say, the enteral nutritional product of the present invention is intended either as a nutritional supplement, or as a sole source of nutrition.
  • the quantity of this supplement consumed per day may be in the range of 1 to 10 8 fluid ounce servings, or as recommended by an attending physician to meet the specific metabolic needs of the patient.
  • the nutritional regimen should be one which takes into consideration the problems of diarrhea, vomiting, anorexia and damage to the intestinal architecture which can occur during such periods of therapy.
  • the nutritional product of the present invention contains ⁇ - carotene, carnitine and taurine, while the general nutritional supplement provides none of these nutrients.
  • /3-carotene is a carotenoid compound that has pro-vitamin A activity.
  • 0-carotene is not associated with toxicity and, therefore, may be used as a source of retinol equivalents in the diet without inducing toxicity concerns.
  • Vitamin A has been shown to reverse some of the immunosuppression associated with thermal injury and radiation injury.
  • Favorable effects on the immune system also have been observed with 3-carotene supplementation.
  • the nutritional product of the present invention contains about 4,900 to 5,700 ⁇ g per liter (about 1,160 to 1,350 ⁇ g per 8 ounce serving) of /3-carotene).
  • the nutritional product of the present invention contains about 84.5 to 109.8 mg per liter (about 20 to 26 mg per 8 fluid ounces) of carnitine.
  • the nutritional product of the present invention contains about 84.5 to 109.8 mg per liter (about 20 to 26 mg per 8 fluid ounces) of taurine.
  • dietary fiber and/or “total dietary fiber” is understood to mean plant material that is undigested by human alimentary enzymes. Dietary fiber is known to be beneficial in regulating bowel function in diarrhea. Inclusion of dietary fiber in the diet also stimulates the renewal of intestinal epithelial cells and ucosal growth.
  • the nutritional product of the present invention contains about 10.6 to 13.5 grams per liter (2.5 to 3.2 grams per 8 fluid ounces) of dietary fiber.
  • the dietary fiber system comprises by weight about 50% soy polysaccharide, 42.5% gum arabic, and 7.5% carboxymethylcellulose (CMC).
  • CMC carboxymethylcellulose
  • any suitable source of dietary fiber may be used without varying from the scope of the invention.
  • the specifications for acronutrients, trace and ultratrace minerals in the nutritional product of the present invention are presented in Table 2.
  • the specifications for vitamins and conditionally essential nutrients in the nutritional product of the present invention are presented in Table 3.
  • the nutritional product of the present invention has a fat blend which comprises canola oil, medium chain triglycerides (MCT oil), high oleic safflower oil and fish oil.
  • a fish oil which is suitable for use in the nutritional product of the present invention is manufactured from sardines and has been obtained from Mochida International in Shinjuku-ku, Tokyo, Japan.
  • a disadvantage of using fish oil is that is should be stored under nitrogen with refrigeration until used to minimize oxidation and even then has a fairly short storage life.
  • the fish oil comprises, by weight, about 10% of the oil blend.
  • the fish oil and canola oil are important components of the oil blend because they are rich in n-3 fatty acids.
  • the fatty acid profile of the nutritional product of the present invention is presented in Table 4.
  • An especially desirable feature of this fatty acid profile is that, by weight, the ratio of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids is in the range of 1.37 to 1.730.
  • Such a characteristic of the fatty acid profile is desirable because, for example, a larger portion of the fatty acids being from the n-3 group tends to result in decreased production in the cancer patient of cytokines which promote cachexia.
  • Fat content in the nutritional product of the present invention is in the range of about 39.0 to 43.0 g per liter (9.2 to 10.1 g per 8 fluid oz.).
  • Linoleic (18:2n-6) 13.7-16.0
  • Protein is provided in the nutritional product of the present invention by a combination of a soy protein isolate and sodium caseinate.
  • a soy protein isolate that has been used to manufacture a nutritional product according to the present invention is PP750 which is a slightly hydrolyzed soy protein isolate which has obtained from Protein Technologies International, St. Louis, Missouri, U.S.A..
  • the nutritional product may be manufactured using an intact soy protein isolate, the resultant viscosity of the nutritional product may be unacceptably high.
  • the protein content of a nutritional product according to the present invention is about 55.0 to 76.0 grams per liter (13.0 to 18.0 grams per 8 fluid ounces). This level of protein is desirable in the nutritional product because it provides an excellent calorie to nitrogen ratio and high levels of all essential amino acids.
  • the amino acid profile of the nutritional product of the present invention is presented in Table 5.
  • Carbohydrates are provided in the nutritional product of the invention by sucrose and hydrolyzed cornstarch, but it is understood that any suitable source(s) of carbohydrates may be used.
  • the nutritional product of the present invention contains about 180 to 200 g per liter (42.5 to 47.2 g per 8 fluid oz.) of carbohydrates.
  • the caloric density of the nutritional product of the present invention is about 1.20 to 1.50 calories/ml, preferably about 1.30 to 1.40 calories/ml. This relatively high caloric density is desirable because it provides high caloric, vitamin and nutrient values in a low volume of the product for patients who may have reduced intake capacity.
  • the osmolality of the nutritional product of the present invention is about 300 to 700 mos /kg water, preferably about 400 to 625 mosm/kg water.
  • This osmolality value is designed to deliver low osmotic load to nutrient ratios, reducing osmotic load while delivering maximal nutrient concentration with a low risk of diarrhea.
  • the viscosity of the nutritional product of the present invention is about 30 to 80 cps, preferably about 40 to 65 cps.
  • the embodiment which contains oat fiber has a viscosity of about 30.1 to 41.0 cps, while the embodiment which does not contain oat fiber has a viscosity of about 38.9 - 63.2 cps.
  • This range of viscosities allows the nutritional product to be ingested either orally or via a feeding tube (e.g. nasogastric, gastrostomy, jejunostomy, or any other suitable enteral route).
  • This nutritional product is not designed for delivery through a central line into the bloodstream. While this nutritional product has only been manufactured in a liquid form, it is understood that it could be manufactured in a powdered form, for reconstitution with an appropriate liquid, without departing from the scope of the present invention.
  • a nutritional product in accordance with the present invention has been produced using the preceding Bill of Materials and the manufacturing process described below. However, it is understood that the manufacturing process may be altered based upon available equipment and other variables.
  • An oil blend containing dietary fiber is prepared by the following procedure.
  • the canola oil, medium chain triglycerides and high oleic safflower oil are placed together in a blend tank and the resulting oil blend is heated to a temperature in the range of about 43-52 ⁇ C.
  • the soy lecithin, oil soluble vitamin premix, Vitamin A palmitate and beta carotene are added to the oil blend.
  • While maintaining the temperature of the oil blend in the range of 43-52 ⁇ C the fish oil is added thereto.
  • a protein slurry is prepared by the following procedure. Place about 199.3 kg of water in a vessel and heat the water to a temperature in the range of about 60-71°C. Add the oat fiber to the water. When the oat fiber has been dispersed, add the sodium caseinate to the heated water. After the protein has been dissolved, maintain the temperature of the resultant slurry in the range of about 43-54°C. Add the remainder of the soy protein isolate to the slurry, and continue to maintain the slurry at a temperature in the range of about 43-54°C until it is combined with additional product ingredients.
  • An oat fiber which is suitable for use in the practice of the present invention comprises ground up oat hulls that have been treated in the manner taught in U.S. Patent No. 4,806,875, and may be obtained from Opta Food Ingredients, Inc. of Cambridge, Massachusetts, U.S.A.
  • the oat fiber is eliminated and, as indicated in the Bill of Materials, a larger quantity of soy polysaccharide is used.
  • a larger quantity of soy polysaccharide is used.
  • only about 30% of the soy protein isolate is added to the oil blend and the remainder of the soy protein isolate is added to this protein slurry. If there is no oat fiber in the formulation, but more soy polysaccharide, (all of which must be added to the oil blend), not as much soy protein isolate can be accommodated in the oil blend, so more soy protein isolate is added to the protein slurry in place of the oat fiber.
  • a carbohydrate/mineral slurry is prepared by the following procedure. Place about 71.7 kg of water in a vessel and heat the water to a temperature in the range of about 60-71°C. (Note in the all- soy polysaccharide alternative embodiment about 62.2 kg of water is used.) Add to the water the magnesium chloride, potassium citrate, potassium chloride and potassium iodide. Agitate the resultant mixture until these ingredients have been dissolved/suspended, and the mixture is uniform in appearance. Add the ultra trace mineral/trace mineral (UTM/TM) premix to the mixture.
  • UDM/TM ultra trace mineral/trace mineral
  • the UTM/TM premix contains zinc sulfate, ferrous sulfate, manganese sulfate, copper sulfate, sodium selenite, chromium chloride, sodium molybdate and citric acid, with sucrose used as a diluent).
  • the slurry should be green in color.
  • the magnesium phosphate, calcium carbonate and tricalcium phosphate are then added to the slurry.
  • the sucrose and hydrolyzed cornstarch are added to the slurry, and the slurry is agitated until these ingredients have been dissolved.
  • the resultant carbohydrate/mineral slurry is continuously agitated and maintained at a temperature in the range of about 60-71°C until it is combined with additional product ingredients.
  • the three slurries/blends which have been prepared are then blended together by the following procedure. Combine the protein slurry with the oil blend containing dietary fiber with agitation. To the resultant blend add the carbohydrate/mineral slurry, and mix the blend thoroughly. Adjust the temperature of the resultant product blend to be in the range of about 49-57°C. The pH of the product blend should be in the range of 6.45 - 6.70, and if necessary IN potassium hydroxide is added to bring the pH of the product blend into the specified range.
  • the product blend is processed as follows:
  • the product blend is emulsified with a homogenizer at about 900-1100 psig.
  • the product blend is heated by steam injection to a temperature in the range of about 144-148°C and held at this temperature for about 5 seconds.
  • the product blend is flash cooled to a temperature in the range of about 120-122°C.
  • the product blend is further cooled to a temperature in the range of about 71-79°C.
  • the product blend is held at a temperature in the range of about 74-85°C for 16 seconds.
  • the nutritional product of the present invention is manufactured on a large scale that rather than adding the fish oil to the oil blend, the fish oil should be metered into the product blend at a constant rate just prior to emulsification to improve dispersion of the fish oil throughout the final blend.
  • dilution water is added to the blend. If a vanilla flavored product is being produced add 27.4 kg of dilution water; if a strawberry flavored product is being produced add 33.1 kg of dilution water.
  • a vitamin solution is prepared by the following procedure. About 9.2 kg of water is placed in a vessel and adjusted to a temperature in the range of about 10-43°C. The ascorbic acid is added to the water which is agitated until the ascorbic acid is dissolved therein. The resultant solution is neutralized with 45% potassium hydroxide. The choline chloride, L- carnitine and taurine are added to the solution and blended until dissolved.
  • a flavor solution is prepared and added to the product blend with agitation. If a vanilla flavored product is being manufactured, add (a) the natural and artificial vanilla and (b) the artificial creamy vanilla to 10.2 kg of water. If a strawberry flavored product is being manufactured add the artificial strawberry to 3.3 kg of water.
  • a color-in water solution is prepared by mixing the FD&C Red #3 in about 1.8 kg of water. The color-in-water solution is then added to the product blend with agitation.
  • the resultant nutritional product of the present invention may then be placed in suitable containers, for example 8 ounce cans, which are then sealed with suitable closures.
  • suitable containers for example 8 ounce cans, which are then sealed with suitable closures.
  • the product should be sealed in containers within 48 hours after completion of the standardization/flavoring procedures.
  • the nutritional product may then be sterilized using suitable procedures which are well known in the art.

Abstract

A liquid enteral nutritional product has been formulated which has utility, for example, for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy. The nutritional product is characterized by a fatty acid profile wherein, by weight: (a) the ratio of the sum of the n-3 to n-6 fatty acids is in the range of 1.37 to 1.70; (b) Eicosapentaenoic Acid (23:6n-3) is about 2.7-3.0 % of total fatty acids; and (c) Docosahexaenoic Acid (22:6n-3) is about 1.3-1.4 % of total fatty acids. Preferably the nutritional product also contains intact protein, β-carotene, carnitine and taurine.

Description

ENTERAL NUTRITIONAL PRODUCT
The present invention relates to an enteral nutritional supplement, for example for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy.
Cancer patients typically undergo intermittent periods of chemotherapy and/or radiation therapy during which their nutritional needs are different from the periods between therapy treatments. It is preferred that when the patient is not receiving intensive therapy a well balanced enteral diet be consumed. However, decreased appetite and changes in taste perceptions due to therapies may result in inadequate nutritional intake. Therefore, the consumption of an enteral nutritional supplement may be required.
The nutritional product of the present invention is formulated to provide enteral nutritional supplementation, for example for a person afflicted with cancer, during a period of time when the person is not undergoing intensive chemotherapy and/or radiation therapy. That is to say, the enteral nutritional product of the present invention is intended either as a nutritional supplement, or as a sole source of nutrition. The quantity of this supplement consumed per day may be in the range of 1 to 10 8 fluid ounce servings, or as recommended by an attending physician to meet the specific metabolic needs of the patient.
During the times that a person afflicted with cancer is not undergoing intensive chemotherapy and/or radiation therapy the nutritional regimen should be one which takes into consideration the problems of diarrhea, vomiting, anorexia and damage to the intestinal architecture which can occur during such periods of therapy.
Examples of commercial products which are general nutritional supplements are ENSURE® and ENSURE® WITH FIBER, both of which are available from Ross Laboratories, a Division of Abbott Laboratories, of Columbus, Ohio U.S.A. Inasmuch as the nutritional product of the present invention contains fiber, it is compared with ENSURE® WITH FIBER in Table 1 to show the major differences in the nutritional profiles of these products. TABLE 1
NUTRIENT TARGET SPECIFICATIONS
NEW PRODUCT ENSURE® WITH ENSURE® WITH
FIBER FIBER
In 8 Fliuid Oz. In Liter In 8 Fluid Oz. In Liter
Protein, g 14.8 62.5 9.4 39.7
Fat, g 9.4 39.7 8.8 37.1
Carbohydrate, g 43.0 181.7 38.3 161.8
Total Dietary Fiber, g 2.5 10.6 3.4 14.4
/3-Carotene, μg 1160 4901 -0- -0-
Folic Acid,μg 21.0 88.7 102 431
Carnitine, mg 20 84.5 -0- -0-
Taurine, mg 20 84.5 -0- -0-
The nutritional product of the present invention contains β- carotene, carnitine and taurine, while the general nutritional supplement provides none of these nutrients. /3-carotene is a carotenoid compound that has pro-vitamin A activity. However, unlike vitamin A, 0-carotene is not associated with toxicity and, therefore, may be used as a source of retinol equivalents in the diet without inducing toxicity concerns. Vitamin A has been shown to reverse some of the immunosuppression associated with thermal injury and radiation injury. Favorable effects on the immune system also have been observed with 3-carotene supplementation. The nutritional product of the present invention contains about 4,900 to 5,700 μg per liter (about 1,160 to 1,350 μg per 8 ounce serving) of /3-carotene).
Although carnitine and taurine are present in low but adequate levels in a normal diet, these conditionally essential nutrients may become limiting under some circumstances. Carnitine deficiency has been observed in sepsis and trauma and during long-term enteral nutrition support. Evidence of taurine depletion has been demonstrated after surgical trauma and a decline in serum taurine concentrations during metabolic stress suggests that taurine supplementation is needed in that state. In humans intensive cytoxic chemotherapy is known to reduce taurine levels. The nutritional product of the present invention contains about 84.5 to 109.8 mg per liter (about 20 to 26 mg per 8 fluid ounces) of carnitine. The nutritional product of the present invention contains about 84.5 to 109.8 mg per liter (about 20 to 26 mg per 8 fluid ounces) of taurine.
As used herein and in the claims "dietary fiber" and/or "total dietary fiber" is understood to mean plant material that is undigested by human alimentary enzymes. Dietary fiber is known to be beneficial in regulating bowel function in diarrhea. Inclusion of dietary fiber in the diet also stimulates the renewal of intestinal epithelial cells and ucosal growth. The nutritional product of the present invention contains about 10.6 to 13.5 grams per liter (2.5 to 3.2 grams per 8 fluid ounces) of dietary fiber. In a preferred embodiment the dietary fiber system comprises by weight about 50% soy polysaccharide, 42.5% gum arabic, and 7.5% carboxymethylcellulose (CMC). However, any suitable source of dietary fiber may be used without varying from the scope of the invention.
The specifications for acronutrients, trace and ultratrace minerals in the nutritional product of the present invention are presented in Table 2. The specifications for vitamins and conditionally essential nutrients in the nutritional product of the present invention are presented in Table 3.
Figure imgf000007_0001
TABLE 2 MINIMUM SPECIFICATIONS FOR MACRONUTRIENTS, TRACE, AND ULTRATRACE MINERALS
NUTRIENT UNI1 ACCEPTABLE RANGE TARGETS (Units/100 g) (Units/100 g) (Units/8 oz) (Units/Liter)
Protein g 5.75 - 5.85 5.69 14.8 62.5
Fat g 3.65 - 3.85 3.62 9.4 39.7
Carbohydrate g 16.7 - 18.1 16.54 43.0 181.7
Total Dietary Fibers g 1.03 - 1.22 0.96 2.5 10.6
Calcium mg 83.4 • 96.2 83.4 217 916.8
Phosphorus mg 83.4 - 96.2 83.4 217 916.8
Magnesium mg 32.1 - 38.5 32.1 83 350.7
Sodium mg 79.6 - 97.3 88.5 230 971.8
Potassium g 124.2 - 151.8 138.5 360 1521
Chloride mg 110.8 - 135.4 123.1 320 1352
Iodine μg 9.6 - 25.8 9.6 25 105.6
Iron mg 1.35 - 1.90 1.35 3.51 14.8
Zinc mg 1.76 - 2.51 1.76 4.58 19.4
Manganese mg 0.38 - 0.53 0.38 0.99 4.2
Copper mg 0.16 - 0.22 0.16 0.42 1 .8
Selenium μg 5.41 - 8.14 5.38 14.0 59.2
Chromium μg 5.92 - 15.3 5.92 15.4 65. 1
Molybdenum μg 12.4 - 19.2 12.4 32.2 136
TABLE 3 SPECIFICATIONS FOR VITAMINS AND CONDITIONALLY ESSENTIAL NUTRIENTS
NUTRIENT UNITS MINIMUM TARGET SPECIFICATIONS
(Units/Liter) (Uniits/8 fluid oz)
Vitamin A IU 3523 835
/3-carotene μg 4895 1160
Vitamin D IU 282 66.7
Vitamin E IU 21.1 5.0
Vitamin K μg 56.1 13.3
Folic Acid μg 88.7 21.0
Niacin mg 14.1 3.34
Riboflavin mg 1.22 0.29
Thiamin mg 1.05 0.25
Pyridoxine mg 1.41 0.33
Cyanocobalamin μg 4.22 1.00
Pantothenate mg 7.05 1.67
Biotin μg 211 50
Ascorbic Acid mg 211 50
Choline mg 140 33.3
Carnitine mg 84 20
Taurine mg 84 20
The nutritional product of the present invention has a fat blend which comprises canola oil, medium chain triglycerides (MCT oil), high oleic safflower oil and fish oil. A fish oil which is suitable for use in the nutritional product of the present invention is manufactured from sardines and has been obtained from Mochida International in Shinjuku-ku, Tokyo, Japan. A disadvantage of using fish oil is that is should be stored under nitrogen with refrigeration until used to minimize oxidation and even then has a fairly short storage life. Preferably, the fish oil comprises, by weight, about 10% of the oil blend. The fish oil and canola oil are important components of the oil blend because they are rich in n-3 fatty acids. The fatty acid profile of the nutritional product of the present invention is presented in Table 4. An especially desirable feature of this fatty acid profile is that, by weight, the ratio of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids is in the range of 1.37 to 1.730. Such a characteristic of the fatty acid profile is desirable because, for example, a larger portion of the fatty acids being from the n-3 group tends to result in decreased production in the cancer patient of cytokines which promote cachexia. Fat content in the nutritional product of the present invention is in the range of about 39.0 to 43.0 g per liter (9.2 to 10.1 g per 8 fluid oz.).
TABLE 4 FATTY ACID PROFILE
FATTY ACID % of TOTAL FATTY ACIDS (by weight)
Caprylic (8:0) 10.3-12.1
Capric (10:0) 7.0-8.3
Laurie (12:0) about 0.2
Myristic (14:0) 0.6-0.7
Palmitic (16:0) 4.1-4.8
Palmitoleic (16:ln7) 0.9-1.0
Stearic (18:0) 1.5-1.7
Oleic (18:ln-9) 44.2-46.3
Linoleic (18:2n-6) 13.7-16.0
Alpha-Linolenic (18:3n-3) 4.7-5.3
Stearidonic (18:4n-3) about 0.4
Eicosenoic (20:ln-9) 1.0-1.1
Eicosapentaenoic (20:J Sn-3)(EPA) 2.7-3.0
Behenic (22:0) about 0.3
Erucic (22:ln-9) 0.4-0.5
Docosapentaenoic (22:]ln-9) about 0.2
Docsahexaenoic (22:6n- -3)(DHA) 1.3-1.4
Nervonic (24:ln-9) 0.0-0.1
Others 0.4-1.1
% Total n-3 fatty acids 9.4-10.4 (by weight)
% Total n-6 fatty acids 13.7-16.0 (by weight)
% Total n-6/Total n-3 fatty acids 1.37 - 1.70 (by weight)
% EPA + DHA 4.0-4.4 (by weight)
Protein is provided in the nutritional product of the present invention by a combination of a soy protein isolate and sodium caseinate. A soy protein isolate that has been used to manufacture a nutritional product according to the present invention is PP750 which is a slightly hydrolyzed soy protein isolate which has obtained from Protein Technologies International, St. Louis, Missouri, U.S.A.. Although the nutritional product may be manufactured using an intact soy protein isolate, the resultant viscosity of the nutritional product may be unacceptably high. The protein content of a nutritional product according to the present invention is about 55.0 to 76.0 grams per liter (13.0 to 18.0 grams per 8 fluid ounces). This level of protein is desirable in the nutritional product because it provides an excellent calorie to nitrogen ratio and high levels of all essential amino acids. The amino acid profile of the nutritional product of the present invention is presented in Table 5.
TABLE 5
AMINO ACID PROFILE
AMINO ACID g/lOOg sample g/lOOg protein
1of product
Aspartic Acid 0.488 8.34
Threonine* 0.253 4.32
Serine 0.343 5.86
Glutamic Acid 1.266 21.64
Proline 0.581 9.93
Glycine 0.141 2.41
Alanine 0.197 3.37
Valine* 0.331 5.66
Methionine* 0.141 2.41
Isoleucine* 0.271 4.63
Leucine* 0.538 9.20
Tyrosine 0.273 4.67
Phenylalanine 0.293 5.01
Histidine* 0.158 2.70
Lysine* 0.426 7.28
Arginine 0.252 4.31
Tryptophan* 0.071 1.21
Cr stine 0.042 0.72
Total 6.066 103.67
Available Lysine 0.380g/100g sample Taurine 6.91 mg/lOOg sample
* Essential Amino Acid
Actual protein = 5.85g/100g sample of product
Carbohydrates are provided in the nutritional product of the invention by sucrose and hydrolyzed cornstarch, but it is understood that any suitable source(s) of carbohydrates may be used. Preferably, the nutritional product of the present invention contains about 180 to 200 g per liter (42.5 to 47.2 g per 8 fluid oz.) of carbohydrates. The caloric density of the nutritional product of the present invention is about 1.20 to 1.50 calories/ml, preferably about 1.30 to 1.40 calories/ml. This relatively high caloric density is desirable because it provides high caloric, vitamin and nutrient values in a low volume of the product for patients who may have reduced intake capacity.
The osmolality of the nutritional product of the present invention is about 300 to 700 mos /kg water, preferably about 400 to 625 mosm/kg water.
This osmolality value is designed to deliver low osmotic load to nutrient ratios, reducing osmotic load while delivering maximal nutrient concentration with a low risk of diarrhea.
The viscosity of the nutritional product of the present invention is about 30 to 80 cps, preferably about 40 to 65 cps. There are two embodiments of the invention disclosed herein, one of which contains oat fiber and one which does not contain oat fiber. The embodiment which contains oat fiber has a viscosity of about 30.1 to 41.0 cps, while the embodiment which does not contain oat fiber has a viscosity of about 38.9 - 63.2 cps. This range of viscosities allows the nutritional product to be ingested either orally or via a feeding tube (e.g. nasogastric, gastrostomy, jejunostomy, or any other suitable enteral route). This nutritional product is not designed for delivery through a central line into the bloodstream. While this nutritional product has only been manufactured in a liquid form, it is understood that it could be manufactured in a powdered form, for reconstitution with an appropriate liquid, without departing from the scope of the present invention.
MANUFACTURING PROCESS
The Bill of Materials for manufacturing a 445 kg batch of a nutritional product in accordance with the invention is presented in Table 6. It is understood that this Bill of Materials has been used to make a nutritional product in accordance with the present invention, but could be altered in ingredients and quantities of ingredients without varying from the scope of the present invention.
TABLE 6
BILL OF MATERIALS
INGREDIENT AMOUNT for 454 kg (1000 lbs)
Canola oil 81.4 kg
MCT oil 3.26 kg
High Oleic Safflower Oil 3.26 kg
Soy Lecithin 0.74 kg
Oil Soluble Vitamin Premix 24.60 g
Vitamin D3 0.158 9
Vitamin E 17.67 g
Vitamin 0.033 g
Vitamin A palmitate 2.000 g jS-Carotene 9.790 g
Fish Oil 1.63 kg
Soy Polysaccharide* 1.08 kg
Gum Arabic 2.10 kg
Carboxymethlycel1ulose 362.87 g
Soy Protein Isolate 5.82 kg
Sodium Caseinate 22.72 kg
Water 315.21 kg
Oat Fiber* 1.42 kg
Magnesium Chloride 0.73 kg
Potassium Citrate 0.99 kg
Potassium Chloride 351.50 g
Potassium Iodide 0.057 g
UTM/TM Premix 103.20 g
Zinc 8.548 g
Iron 6.504 g
Manganese 1.815 g
Copper 0.767 g
Selenium 0.028 g
Chromium 0.031 g
Molybdenum 0.060 g
Magnesium Phosphate 296.81 g
Calcium Carbonate 427.02 g
Tricalcium Phosphate 0.65 kg
Sucrose 11.92 kg
Hydrolyzed Cornstarch 71.09 kg
Ascorbic Acid 207.00 g
Choiine Chloride 82.00 g
L-Carnitine 40.00 g
Taurine 40.00 g
Niacinamide 7.655 g d-Ca Pantothenate 5.098 g
Biotin 0.166 g
Pyridoxine HCL 1.328 g
Folic Acid 0.054 g
Thiamine HCL 1.531 g
Cyanocobalamin 0.004 g
Riboflavin 0.977 g
Natural and Artificial Van-ilia** 0.68 kg
Artificial Creamy Vanilla ** 0.45 kg
Artificial Strawberry *** 362.87 g
FDC Red # 3 *** 18.14 g * In an alternative formulation no oat fiber is used and the quantity of soy polysaccharide is increased to 2.69 kg.
** These ingredients are used only when making a vanilla flavored product.
*** These ingredients are included only when making a strawberry flavored product.
A nutritional product in accordance with the present invention has been produced using the preceding Bill of Materials and the manufacturing process described below. However, it is understood that the manufacturing process may be altered based upon available equipment and other variables.
An oil blend containing dietary fiber is prepared by the following procedure. The canola oil, medium chain triglycerides and high oleic safflower oil are placed together in a blend tank and the resulting oil blend is heated to a temperature in the range of about 43-52βC. The soy lecithin, oil soluble vitamin premix, Vitamin A palmitate and beta carotene are added to the oil blend. While maintaining the temperature of the oil blend in the range of 43-52βC the fish oil is added thereto. Add the soy polysaccharide to the oil blend, and agitate the oil blend thoroughly. Add the gum arabic to the oil blend, and mix the oil blend until no clumping appears. Add the carbomethylcellulose to the oil blend, and mix until the blend is uniformly dispersed, without any clumping. Add about 70% of the soy protein isolate to the blend. Adding some of the soy protein isolate to the oil blend instead of putting all of the soy protein isolate in the protein slurry facilitates easier mixability of the protein slurry while maintaining the oil blend at a pu pable viscosity level. Maintain the resultant oil blend with fiber at a temperature in the range of about 43- 52βC, with agitation, until it is combined with additional product ingredients.
A protein slurry is prepared by the following procedure. Place about 199.3 kg of water in a vessel and heat the water to a temperature in the range of about 60-71°C. Add the oat fiber to the water. When the oat fiber has been dispersed, add the sodium caseinate to the heated water. After the protein has been dissolved, maintain the temperature of the resultant slurry in the range of about 43-54°C. Add the remainder of the soy protein isolate to the slurry, and continue to maintain the slurry at a temperature in the range of about 43-54°C until it is combined with additional product ingredients.
An oat fiber which is suitable for use in the practice of the present invention comprises ground up oat hulls that have been treated in the manner taught in U.S. Patent No. 4,806,875, and may be obtained from Opta Food Ingredients, Inc. of Cambridge, Massachusetts, U.S.A.
In an alternative embodiment the oat fiber is eliminated and, as indicated in the Bill of Materials, a larger quantity of soy polysaccharide is used. In such an alternative embodiment only about 30% of the soy protein isolate is added to the oil blend and the remainder of the soy protein isolate is added to this protein slurry. If there is no oat fiber in the formulation, but more soy polysaccharide, (all of which must be added to the oil blend), not as much soy protein isolate can be accommodated in the oil blend, so more soy protein isolate is added to the protein slurry in place of the oat fiber. These adjustments facilitate maintaining the mixability and pumpability of the blends and slurries.
A carbohydrate/mineral slurry is prepared by the following procedure. Place about 71.7 kg of water in a vessel and heat the water to a temperature in the range of about 60-71°C. (Note in the all- soy polysaccharide alternative embodiment about 62.2 kg of water is used.) Add to the water the magnesium chloride, potassium citrate, potassium chloride and potassium iodide. Agitate the resultant mixture until these ingredients have been dissolved/suspended, and the mixture is uniform in appearance. Add the ultra trace mineral/trace mineral (UTM/TM) premix to the mixture. (Preferably the UTM/TM premix contains zinc sulfate, ferrous sulfate, manganese sulfate, copper sulfate, sodium selenite, chromium chloride, sodium molybdate and citric acid, with sucrose used as a diluent). At this time the slurry should be green in color. The magnesium phosphate, calcium carbonate and tricalcium phosphate are then added to the slurry. The sucrose and hydrolyzed cornstarch are added to the slurry, and the slurry is agitated until these ingredients have been dissolved. The resultant carbohydrate/mineral slurry is continuously agitated and maintained at a temperature in the range of about 60-71°C until it is combined with additional product ingredients.
The three slurries/blends which have been prepared are then blended together by the following procedure. Combine the protein slurry with the oil blend containing dietary fiber with agitation. To the resultant blend add the carbohydrate/mineral slurry, and mix the blend thoroughly. Adjust the temperature of the resultant product blend to be in the range of about 49-57°C. The pH of the product blend should be in the range of 6.45 - 6.70, and if necessary IN potassium hydroxide is added to bring the pH of the product blend into the specified range.
The product blend is processed as follows:
(a) The product blend is heated to a temperature in the range of about 68-74°C. (b) The product blend is deaerated at 10-15 in Hg.
(c) The product blend is emulsified with a homogenizer at about 900-1100 psig.
(d) The product blend is heated to a temperature in the range of about 120-122°C.
(e) The product blend is heated by steam injection to a temperature in the range of about 144-148°C and held at this temperature for about 5 seconds.
(f) The product blend is flash cooled to a temperature in the range of about 120-122°C.
(g) The product blend is further cooled to a temperature in the range of about 71-79°C.
(h) The product blend is homogenized at 3,900-4,100/400-600 psig.
(i) The product blend is held at a temperature in the range of about 74-85°C for 16 seconds.
(j) The product blend is cooled to a temperature in the range of about 1-7°C, and stored at this temperature to minimize microbial growth until further ingredients are added thereto.
It is recommended that if the nutritional product of the present invention is manufactured on a large scale that rather than adding the fish oil to the oil blend, the fish oil should be metered into the product blend at a constant rate just prior to emulsification to improve dispersion of the fish oil throughout the final blend.
At the time that the vitamins and flavors are added to the blend dilution water is added to the blend. If a vanilla flavored product is being produced add 27.4 kg of dilution water; if a strawberry flavored product is being produced add 33.1 kg of dilution water.
A vitamin solution is prepared by the following procedure. About 9.2 kg of water is placed in a vessel and adjusted to a temperature in the range of about 10-43°C. The ascorbic acid is added to the water which is agitated until the ascorbic acid is dissolved therein. The resultant solution is neutralized with 45% potassium hydroxide. The choline chloride, L- carnitine and taurine are added to the solution and blended until dissolved. Add the following water soluble vitamins to the solution: niacinamide, d-Ca Pantothenoic acid, biotin, pyridoxine HCL, folic acid, thiamine HCL, cyanocobalamin, and riboflavin (note that it would be desirable to provide the water soluble vitamins in a premix, but such a premix was not yet developed at the time of filing a patent application for the new nutritional product disclosed herein). The pH of the resultant solution should be in the range of about 6.0-10.0. The vitamin solution is then added to the product blend.
A flavor solution is prepared and added to the product blend with agitation. If a vanilla flavored product is being manufactured, add (a) the natural and artificial vanilla and (b) the artificial creamy vanilla to 10.2 kg of water. If a strawberry flavored product is being manufactured add the artificial strawberry to 3.3 kg of water.
If a strawberry flavored product is being manufactured, a color-in water solution is prepared by mixing the FD&C Red #3 in about 1.8 kg of water. The color-in-water solution is then added to the product blend with agitation.
The resultant nutritional product of the present invention may then be placed in suitable containers, for example 8 ounce cans, which are then sealed with suitable closures. The product should be sealed in containers within 48 hours after completion of the standardization/flavoring procedures. The nutritional product may then be sterilized using suitable procedures which are well known in the art.

Claims

CLAIMS :
1. A liquid enteral nutritional product comprising fat, carbohydrates and dietary fiber and a source of intact protein the nutritional product containing, about 4,900 to 5,700 μg of |S-carotene per liter, and the nutritional product has a fatty acid profile wherein, by weight: (a) the ratio of the sum of the n-6 fatty acids to the sum of the n-3 fatty acids is in the range of 1.37 to 1.70; (b) the percentage of total fatty acids comprising Eicosapentaenoic Acid (20:5n-3) is in the range of 2.7 to 3.0%; and (c) the percentage of total fatty acids comprising Docosahexaenoic Acid (22:6n-3) is in the range of 1.3 to 1.4%.
2. A liquid enteral nutritional product as described in claim 1 further comprising about 10.6 to 13.5 mg of carnitine per liter.
3. A liquid enteral nutritional product as described in claim 1 further comprising about 10.6 to 13.5 mg of taurine per liter.
4. A liquid enteral nutritional product as described in claim 1 further comprising about 1.6 to 13.5 mg of carnitine per liter and about 10.6 to 13.5 mg of taurine per liter.
5. A liquid enteral nutritional product as described in claim 1 wherein the fat comprises fish oil.
6. A liquid enteral nutritional product as described in claim 1 which has a caloric density of about 1.20 to 1.50 calories per ml.
7. A liquid enteral nutritional product as described in claim 1 wherein the dietary fiber comprises a combination of soy polysaccharide, gum arabic and carboxy ethylcellulose.
PCT/US1994/005415 1993-05-28 1994-05-11 Enteral nutritional product WO1994027628A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP94917991A EP0700303A4 (en) 1993-05-28 1994-05-11 Enteral nutritional product

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6906793A 1993-05-28 1993-05-28
US6926593A 1993-05-28 1993-05-28
US069,067 1993-05-28
US069,265 1993-05-28

Publications (1)

Publication Number Publication Date
WO1994027628A1 true WO1994027628A1 (en) 1994-12-08

Family

ID=26749648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/005415 WO1994027628A1 (en) 1993-05-28 1994-05-11 Enteral nutritional product

Country Status (3)

Country Link
EP (1) EP0700303A4 (en)
CA (1) CA2162042C (en)
WO (1) WO1994027628A1 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0721742A1 (en) * 1995-01-13 1996-07-17 Clintec Nutrition Company, An Illinois Partnership Nutrition for elderly patients
EP0755634A2 (en) * 1995-07-26 1997-01-29 Hans-Günter Berner GmbH Nutritional supplement
WO2001084961A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
DE19733892C2 (en) * 1996-09-09 2002-06-20 Hadasit Med Res Service Anti-irradiation method
KR100368011B1 (en) * 2000-03-23 2003-01-14 조금호 An enteral solution fortified with taurine
EP0705539B1 (en) * 1994-10-06 2003-01-22 Friesland Brands B.V. A food for pregnant and lactating women
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
EP1800675A1 (en) * 2005-12-23 2007-06-27 Nutricia N.V. Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
JP2010513226A (en) * 2006-10-19 2010-04-30 ネステク ソシエテ アノニム Long-term nutrition supply for the elderly
EP2340825A3 (en) * 2001-11-14 2011-09-07 N.V. Nutricia Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a neurotransmitter precursor
CN113841889A (en) * 2021-08-10 2021-12-28 许昌学院 Cell absorption combined functional nutrient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085883A (en) * 1991-06-27 1992-02-04 Abbott Laboratories Blend of dietary fiber for nutritional products
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5085883A (en) * 1991-06-27 1992-02-04 Abbott Laboratories Blend of dietary fiber for nutritional products
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Abstract, R.A. KARMALI, "Eicosonoids in Neoplasia", Prev. Med., Volume 16, No. 4, issued July 1987, Medline Abstract No. 87317457, pages 493-502, see entire Abstract. *
Nutrition in Clinical Practice, Volume 3, issued October 1988, JOANNE KOUBA, "Nutritional Care of the Individual with Cancer", pages 175-182, especially page 180. *
See also references of EP0700303A4 *

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0705539B1 (en) * 1994-10-06 2003-01-22 Friesland Brands B.V. A food for pregnant and lactating women
US5589468A (en) * 1995-01-13 1996-12-31 Clintec Nutrition Co. Method for providing nutrition to elderly patients
US5686429A (en) * 1995-01-13 1997-11-11 Nestec Ltd Method for providing nutrition to elderly patients
USRE36288E (en) * 1995-01-13 1999-08-31 Nestec Ltd. Method for providing nutrition to elderly patients
USRE37020E1 (en) * 1995-01-13 2001-01-16 Nestec, Ltd. Method for providing nutrition to elderly patients
EP0721742A1 (en) * 1995-01-13 1996-07-17 Clintec Nutrition Company, An Illinois Partnership Nutrition for elderly patients
EP0755634A2 (en) * 1995-07-26 1997-01-29 Hans-Günter Berner GmbH Nutritional supplement
EP0755634A3 (en) * 1995-07-26 1997-08-20 Hans Guenther Berner Gmbh Nutritional supplement
DE19733892C2 (en) * 1996-09-09 2002-06-20 Hadasit Med Res Service Anti-irradiation method
KR100368011B1 (en) * 2000-03-23 2003-01-14 조금호 An enteral solution fortified with taurine
EP1911442A3 (en) * 2000-05-08 2008-05-21 N.V. Nutricia Preparation for the prevention and/or treatment of dementia syndromes
EP2292210A1 (en) * 2000-05-08 2011-03-09 N.V. Nutricia Preparation for the prevention and/or treatment of dementia syndromes
US7208180B2 (en) 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8865687B2 (en) 2000-05-08 2014-10-21 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
EP1911442A2 (en) * 2000-05-08 2008-04-16 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
WO2001084961A2 (en) * 2000-05-08 2001-11-15 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
EP2070519A1 (en) * 2000-05-08 2009-06-17 N.V. Nutricia Preparation for the prevention and/or treatment of dementia syndromes
US7560447B2 (en) 2000-05-08 2009-07-14 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US8377912B2 (en) 2000-05-08 2013-02-19 N. V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
US7772217B2 (en) 2000-05-08 2010-08-10 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
WO2001084961A3 (en) * 2000-05-08 2002-08-15 Nutricia Nv Preparation for the prevention and/or treatment of vascular disorders
EP2316426A1 (en) * 2000-05-08 2011-05-04 N.V. Nutricia Preparation for the prevention and/or treatment of dementia syndromes
EP2340825A3 (en) * 2001-11-14 2011-09-07 N.V. Nutricia Method and preparation preventing and/or treating neurodegenerative or neurological disorders using a neurotransmitter precursor
EP2338483A3 (en) * 2001-11-14 2012-05-23 N.V. Nutricia Method and preparation preventing and/or treating neurodegenerative or neurological disorders using choline
US9504712B2 (en) 2001-11-14 2016-11-29 N.V. Nutricia Preparation for improving the action of receptors
US9844525B2 (en) 2001-11-14 2017-12-19 N.V. Nutricia Preparation for improving the action of receptors
EP2342975A2 (en) 2005-12-23 2011-07-13 N.V. Nutricia Composition for improving membrane composition and functioning of cells
EP1800675A1 (en) * 2005-12-23 2007-06-27 Nutricia N.V. Composition comprising polyunsaturated fatty acids, proteins and manganese and/or molybden for improving membrane composition
EP2342975A3 (en) * 2005-12-23 2014-10-22 N.V. Nutricia Composition for improving membrane composition and functioning of cells
US9446014B2 (en) 2005-12-23 2016-09-20 N. V. Nutricia Composition for improving membrane composition and functioning of cells
US9463176B2 (en) 2005-12-23 2016-10-11 N.V. Nutricia Composition for improving membrane composition and functioning of cells
JP2010513226A (en) * 2006-10-19 2010-04-30 ネステク ソシエテ アノニム Long-term nutrition supply for the elderly
CN113841889A (en) * 2021-08-10 2021-12-28 许昌学院 Cell absorption combined functional nutrient

Also Published As

Publication number Publication date
CA2162042A1 (en) 1994-12-08
EP0700303A4 (en) 1996-08-21
EP0700303A1 (en) 1996-03-13
CA2162042C (en) 1999-02-23

Similar Documents

Publication Publication Date Title
US5700782A (en) Enteral nutritional product
US5714472A (en) Enternal formulation designed for optimized nutrient absorption and wound healing
US5504072A (en) Enteral nutritional composition having balanced amino acid profile
US5719133A (en) Adolescent dietary composition
US5221668A (en) Nutritional product for trauma and surgery patients
US4670268A (en) Enteral nutritional hypoallergenic formula
EP0961552B1 (en) Nutritional support of paediatric patients
CA2320991C (en) Calorically dense nutritional composition
EP1077616B1 (en) Nutritional product for a person having renal failure
US5723446A (en) Enteral formulation designed for optimized nutrient absorption and wound healing
RU2409388C1 (en) Supporting continuous enteral feeding
US5545411A (en) Method for lowering viscosity by use of gum acacia
WO2008046870A1 (en) Long-term feed - cancer patient
CA2162042C (en) Enteral nutritional product
IE860240L (en) Enteral nutritional hypoallergenic compositions
CA2150741A1 (en) Pediatric lipid emulsion
JP2023069186A (en) Nutritive composition, manufacturing method of nutritive composition, and evaluation method of bioavailability of copper in nutritive composition
CN112352948A (en) Casein balanced type total nutrient powder prepared by wet process and preparation method
WO2023120685A1 (en) Nutritional composition
NZ519932A (en) Formulations comprising arachidonic acid (AA) and docosahexanoic acid (DHA) in nutritionally complete beverages
JPH01243970A (en) Artificial high-density liquid diet
CZ287415B6 (en) Adapted milk for infantile nutrition
CA2163379A1 (en) Nutritional composition containing improved dietary nitrogen component

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994917991

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2162042

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994917991

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994917991

Country of ref document: EP